Trial Profile
Efficacy and Safety Comparison of 4-week Treatment Periods of Two Doses [5 μg (2 Actuations of 2.5 μg) and 10 μg (2 Actuations of 5 μg)] of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler, Tiotropium Inhalation Powder Capsule (18μg) Delivered by the HandiHaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Dec 2023
Price :
$35
*
At a glance
- Drugs Tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 27 Apr 2016 New trial record
- 28 Mar 2016 Results of pooled analysis of this and other 5 trials (see profiles: 15373, 51486, 270480, 270485 and 60495) published in the Advances in Therapy